ondansetron has been researched along with Bladder Cancer in 5 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six consecutive patients, who were to be treated with cisplatin-based chemotherapy for testicular or bladder cancer, underwent a single-blind randomized study to compare the antiemetic therapies with dexamethasone (DEX)+ondansetron (OND) and DEX + alizapride (ALI)." | 9.07 | Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. ( Faustini, M; Mangiarotti, B; Nicolai, N; Piva, L; Pizzocaro, G; Salvioni, R, 1993) |
| "To evaluate the appearance of chemotherapy-induced nausea and vomiting, and to compare the antiemetic efficacy of the triple combination of palonosetron, aprepitant and dexamethasone with that of our old regimen using first-generation 5-hydroxytryptamine 3-receptor antagonists and dexamethasone during gemcitabine and cisplatin chemotherapy in patients with advanced urothelial cancer." | 7.81 | Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. ( Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F, 2015) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 6.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Thirty-six consecutive patients, who were to be treated with cisplatin-based chemotherapy for testicular or bladder cancer, underwent a single-blind randomized study to compare the antiemetic therapies with dexamethasone (DEX)+ondansetron (OND) and DEX + alizapride (ALI)." | 5.07 | Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. ( Faustini, M; Mangiarotti, B; Nicolai, N; Piva, L; Pizzocaro, G; Salvioni, R, 1993) |
| "To evaluate the appearance of chemotherapy-induced nausea and vomiting, and to compare the antiemetic efficacy of the triple combination of palonosetron, aprepitant and dexamethasone with that of our old regimen using first-generation 5-hydroxytryptamine 3-receptor antagonists and dexamethasone during gemcitabine and cisplatin chemotherapy in patients with advanced urothelial cancer." | 3.81 | Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. ( Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F, 2015) |
| "Ondansetron is a potent antiemetic and a competitive antagonist at serotonin receptors, which are also involved in modulation of pain." | 2.76 | Effect of intravenous ondansetron on sensory and motor block after spinal anaesthesia with hyperbaric bupivacaine. ( Bala, I; Chopra, K; Podder, S; Samra, T, 2011) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 2.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitamura, H | 1 |
| Takahashi, A | 1 |
| Hotta, H | 1 |
| Kato, R | 1 |
| Kunishima, Y | 1 |
| Takei, F | 1 |
| Horita, H | 1 |
| Masumori, N | 1 |
| Samra, T | 1 |
| Bala, I | 1 |
| Chopra, K | 1 |
| Podder, S | 1 |
| Fassoulaki, A | 1 |
| Melemeni, A | 1 |
| Zotou, M | 1 |
| Sarantopoulos, C | 1 |
| Nicolai, N | 1 |
| Mangiarotti, B | 1 |
| Salvioni, R | 1 |
| Piva, L | 1 |
| Faustini, M | 1 |
| Pizzocaro, G | 1 |
| Akasaka, Y | 1 |
| Taguchi, T | 1 |
| Ota, K | 1 |
| Furue, H | 1 |
| Niitani, H | 1 |
| Tsukagoshi, S | 1 |
| Ariyoshi, Y | 1 |
| Ikeda, M | 1 |
| Ohta, J | 1 |
| Suminaga, M | 1 |
4 trials available for ondansetron and Bladder Cancer
| Article | Year |
|---|---|
Effect of intravenous ondansetron on sensory and motor block after spinal anaesthesia with hyperbaric bupivacaine.
Topics: Anesthesia, Spinal; Anesthetics, Local; Antiemetics; Bupivacaine; Double-Blind Method; Female; Human | 2011 |
Systemic ondansetron antagonizes the sensory block produced by intrathecal lidocaine.
Topics: Aged; Anesthetics, Local; Antiemetics; Double-Blind Method; Female; Humans; Injections, Spinal; Lido | 2005 |
Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; H | 1993 |
[Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestina | 1992 |
1 other study available for ondansetron and Bladder Cancer
| Article | Year |
|---|---|
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2015 |